MARKET

ABEO

ABEO

Abeona Therapeut
NASDAQ
5.14
-0.02
-0.39%
Closed 19:24 03/10 EDT
OPEN
5.24
PREV CLOSE
5.16
HIGH
5.32
LOW
5.11
VOLUME
2.09M
TURNOVER
--
52 WEEK HIGH
7.54
52 WEEK LOW
3.933
MARKET CAP
278.54M
P/E (TTM)
4.649
1D
5D
1M
3M
1Y
5Y
1D
Abeona Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Dow Jones · 20h ago
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target
Benzinga · 20h ago
Early ZEVASKYN Launch Traction and Robust Reimbursement Support Abeona Buy Rating and $20 Target
TipRanks · 21h ago
Abeona Accelerates ZEVASKYN Commercial Momentum and Market Access
TipRanks · 1d ago
Abeona Therapeutics provides business update on momentum in Zevaskyn launch
TipRanks · 1d ago
Abeona says ZEVASKYN launch gains momentum as commercial payer coverage reaches 80% of insured lives
Reuters · 1d ago
ABEONA THERAPEUTICS INC: ADDITIONAL BIOPSIES FOR ZEVASKYN ARE SCHEDULED FOR REMAINDER OF THIS QUARTER.
Reuters · 1d ago
ABEONA THERAPEUTICS® PROVIDES BUSINESS UPDATE HIGHLIGHTING BUILDING MOMENTUM IN ZEVASKYN® COMMERCIAL LAUNCH
Reuters · 1d ago
More
About ABEO
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).

Webull offers Abeona Therapeutics Inc stock information, including NASDAQ: ABEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABEO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABEO stock methods without spending real money on the virtual paper trading platform.